Phalangeal Osteotomy…To Perform or Not to Perform

Category: Bunion Introduction/Purpose: As the hallux valgus deformity progresses, patients can get mild to moderate arthritis of the metatarsophalangeal (MTP) joint. The degenerative process of MTP arthritis results in reactive tissue formation and proliferation of osseous and cartilaginous structures. For some patients, the results in dorsal bone spurs and pain with great toe dorsiflexion of irritation from shoes. Reconstructive procedures provide a surgical option for patients to address pain and functional limitations, prior to subchondral bone cyst formation and loss of joint space. Patients who underwent cheilectomy alone have been shown to have a high failure rate and progress to advanced disease. A phalangeal dorsiflexion osteotomy has become increasingly more popular amongst foot and ankle surgeons with the hopes of decreasing failure rate and improving early outcomes. Methods: This study was a retrospective review of prospectively collected data from 385 patients treated for hallux rigidus at a large academic medical center between July 2015 and November 2016. All patients underwent either a cheilectomy or cheilectomy with phalangeal osteotomy of the MTP joint. Collected patient reported outcomes (PROs) included in this study were SF12 M, SF12P, FAAM, VAS and PASS scores. Mann-Whitney t-test was performed using GraphPad Prism version 7.0b for Mac to compare procedure groups. Exclusion criteria included poly-trauma, revision of same procedure, and lack of pre or post- operative. Results: Eighteen patients met criteria, 8 underwent cheilectomy and 10 had a cheilectomy with osteotomy procedure. The average age was 51.9 amongst the cohort, with a total of 13 female and 5 males. Patients who underwent cheilectomy with osteotomy procedure had better outcomes across all outcome measure scores. When comparing postoperative scores, cheilectomy with osteotomy patients showed significantly higher scores compared to cheilectomy alone patients: SF12-M (56 vs 36, respectively; p=0.0333), and SF12P (52 vs 30, respectively p=0.0095). VAS scores and FAAM scores showed no statistical difference between the two cohorts. Despite surgical intervention, 50% of patients who received cheilectomy alone reported more pain post-operatively compared to no reports of worsening pain in patients who received cheilectomy with osteotomy. Conclusion: Patients with moderate to severe hallux rigidus demonstrate improved functional outcomes with phalangeal osteotomy in conjunction with cheilectomy compared to cheilectomy alone. Further research with larger cohorts would be beneficial to confirm the reports of this study and expand upon aspects of care that contribute to patient satisfaction and performance

Treatment of End-Stage Hallux Rigidus and Impact of Arthrodesis versus Arthroplasty on Patient Reported Outcomes

Category: Bunion, Midfoot/Forefoot Introduction/Purpose: Hallux rigidus is a degenerative disease of the first metatarsophalangeal joint. Severe, end-stage hallux rigidus can become debilitating with surgical intervention becoming necessary once conservative measures and shoe modifications have failed. Joint salvage procedures include metatarsal phalangeal (MTP) arthrodesis and MTP arthroplasty. The purpose of this study was to assess for differences in patient reported outcomes in two cohorts who underwent fusion or joint reconstruction. Methods: This study was a retrospective review of prospectively collected data of 385 patients from an academic medical institution. Patients who underwent surgical intervention from July 2015 to November 2016 were identified based on CPT codes for MTP arthrodesis (28750) and arthroplasty (28293). We extracted outcome scores including SF12-M, SF12-P, FAAM, and VAS scores. Exclusion criteria included poly-trauma, revision procedures, and lack of pre and post-operative outcome scores. Mann- Whitney t-test was performed using GraphPad Prism version 7.0b for Mac to compare procedure groups, with significance define by a p-value of 0.05. Results: A total of eighteen patients met the inclusion criteria, with 6 who underwent arthroplasty and 12 arthrodesis. The average age was 63.7 amongst the cohort, with a total of 16 female and 2 males. Patients who underwent arthrodesis had better outcomes across all parameters. When comparing preoperative and postoperative scores, arthrodesis patients showed greater improvement of SF12-M (arthrodesis 9 vs arthroplasty -2, p=0.05), and SF12-P (9 vs -16, respectively p=0.05) scores. Arthroplasty patients were more likely to have a decrease in their SF-12 scores. VAS scores and FAAM scores showed no statistical difference between the two cohorts. Postoperative VAS scores were worse in 33% of arthroplasty patients despite surgical intervention, compared to 10% of arthrodesis patients. Conclusion: Our results suggests that both procedures provide a statistically significant difference in pain with several patients having a Global Rate of Change that is “very much better”. However, fusion of the metatarsophalangeal joint results in improved pain and functional outcomes for patients with severe hallux rigidus. These findings are consistent with current reports in the literature, which are mostly case series reports. Larger studies are needed to provide appropriate power and better support the findings of this study

Utilizing Cost and Quality Measures to Guide Fixation of MTP Arthritis

Category: Midfoot/Forefoot Introduction/Purpose: Severe hallux rigidus is the 2nd most common disorder of the 1st metatarsophalangeal (MTP) joint and is present on more than 44% of radiographs taken in those over 80 years of age. Arthrodesis has been the proposed method of fixation for 1st MTP pathology. However, joint preserving alternatives to fusion have also been proposed to maintain joint motion and due to the relatively high nonunion rate (5.4%). However, few reports have investigated if the risk of complications from a fusion impact daily activities and functional outcomes. As such, we investigated the cost and quality associated with treatment of severe MTP arthritis to determine the optimal surgical intervention. Methods: This was a retrospective review of 384 patients from a prospectively collected foot and ankle platform registry in a payor-provider healthcare system. Patients who underwent surgical intervention from July 2015 to November 2017 were identified by CPT codes for MPT arthrodesis (28750) and arthroplasty (28293) as well as key words “hallux” and “rigidus”. Patient reported outcome scores were extracted from the medical records including SF12-M, SF12-P, FAAM, and a binary PASS score. Exclusion criteria included poly-trauma, neurological impairment, and revision procedures. The Mann-Whitney test was performed using Minitab 18 to compare procedure groups for the small samples without a normal distribution, and chi squared analysis was used to analyze the PASS score. Significance was defined by a p-value of <0.05. Additionally, cost data was gathered across the institution based on the previously mentioned CPT codes at the same institution, although statistical analysis was limited by reporting of average numbers. Results: A total of 35 patients met inclusion criteria, with 26 arthrodesis and 9 arthroplasty patients. The arthrodesis group had an average age of 63.4 and the arthroplasty group had an average age of 60.1. The arthrodesis group had higher post op scores in measures including SF12-M, SF12-P, FAAM, and PASS. The arthrodesis group also had greater increase in postoperative SF12-P, and FAAM compared to pre-op scores, with the arthroplasty having higher increase in SF12-M. Of these, the differences in PASS score (p=0.02) and the change in SF12-P were significant (p=0.05). Analysis of cost identified 25 logs of MTP arthroplasty with an average cost of $6,538 per case and 79 logs of MTP arthrodesis with an average cost of$5,086. Conclusion: This study suggests that patients treated with arthrodesis for 1st MTP arthritis have improved outcomes with greater cost containment. Although the PASS and SF-12 scores showed significant differences, all of the results including pain scores revealed greater improvement with arthrodesis, with the exception of the SF12 mental. The small cohorts in this study are a limitation, but these, results are consistent with the current literature. However, with both higher outcome scores and lower cost, arthrodesis appears to have significant advantages compared to arthroplasty and further studies can help guide clinical decision making in this patient population

Patient Reported Outcomes in Athletes following ORIF of Jones Fracture

Category: Lesser Toes, Midfoot/Forefoot, Sports Introduction/Purpose: Treatment of fractures to the 5th metatarsal metaphyseal-diaphyseal junction, known as Jones’ fractures, can present challenges in the elite athlete significantly prolonging return to play. Non-operative treatments in elite athletes result in a high incidence of nonunion and secondary fracture. Primary screw fixation remains the standard of care for athletes. However, delayed union and nonunion are still very common despite surgical fixation due to the fracture occurring in a watershed area with decreased healing potential. Bone marrow aspirate concentrate (BMAC) is an autologous source of hematopoeitic and mesenchymal stem cells that has been used in the treatment of poor healing fractures. We hypothesize that open reduction internal fixation (ORIF) augmented with BMAC will improve patient-reported outcome measures following Jones’ fractures in athletes. Methods: This study was a retrospective review of elite athletes that underwent intramedullary screw fixation augmented with BMAC for Jones’ fractures at an academic medical institution. All patients were assessed preoperatively and postoperatively to determine their pain outcomes based on their visual analog score (VAS). Student’s t test was used in statistical comparison of the preoperative and postoperative outcome scores. P < 0.05 was considered significant. Results: A total of 16 elite athletes were treated with ORIF with BMAC for a Jones fracture with a mean age of 22.2 years (range 19–26). There were 9 males and 7 females included in the study. Type of athlete ranged across various sport activities, with all patients functioning at a collegiate and/or professional level of elite athletics. The mean visual analog score for pain decreased from 6.2 preoperatively (range 3-8) to 2.75 postoperatively (range 1-6 p = 0.06). All patients have returned to elite competitive sport activity with reports of minimal to no pain. Conclusion: Intramedullary screw fixation of Jones’ fractures with BMAC results in optimal surgical outcomes in the elite athlete. A higher powered and long-term study with validated patient-reported outcomes is needed to confirm our observations

Arthroplasty or Arthrodesis in the CJR Era

Category: Ankle Arthritis Introduction/Purpose: Ankle arthritis can be a debilitating disease that results in decreased daily activity and chronic morbidity. Many patients elect for surgical intervention to minimize pain and improve function. To curb costs associated with the increasing demand for total joint arthroplasty (TJA) in the growing elderly Medicare population, CMS announced the Comprehensive Care for Joint Replacement (CJR) model, which included total ankle arthroplasty. To provide continued quality care and cost containment, it is necessary to determine the optimal surgical intervention for patients that could fall within the CJR program. Therefore, we sought to determine the impact of surgical fixation on functional outcomes, systemic utilization, and medical expenditures for patients with ankle arthritis. Methods: We reviewed a prospectively collected and maintained database to identify all patients who underwent a total joint replacement from April 2016 to September 2017. Patients were identified based on DRG codes for primary arthritis of a lower extremity joint, then specifically for foot and ankle, as well as CPT codes for ankle arthroplasty (27702) or ankle arthrodesis (27870/28725). Functional outcomes were assessed based on insurance type. The cohorts were matched for age, comorbidities, and gender. Statistical analysis was performed using chi-squared and paired t-test to assess for differences in patient reported outcomes. Descriptive statistical analysis was used to assess for differences in cost between the cohorts. Results: A total of 573 patients were included.There were 48 replacements and 47 fusions. Arthrodesis procedures costs approximately $6,500 less per case than the system costs for patients who underwent arthroplasty procedures. The average length of stay for patients who underwent total ankle arthroplasty was 1.6 days compared to outpatient surgical centers utilized for most arthrodesis patients. Overall, patients reported improved pain and a 30.96 increase in FAAM scores. Most patients had a global rate of change that was “very much better” or “much better” (68$325,000 for a system that supports intervention for ~50 cases per year. As such, these results suggest that arthroplasty may be optimal for patients with severe symptomatic ankle arthritis, while most patients have adequate relief with an ankle fusion. More importantly, quality improvement efforts should focus on the impact of surgical intervention on functional activity

Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure

Numerous genetic loci have been associated with systolic blood pressure (SBP) and diastolic blood pressure (DBP) in Europeans(1-3). We now report genome-wide association studies of pulse pressure (PP) and mean arterial pressure (MAP). In discovery (N = 74,064) and follow-up studies (N = 48,607), we identified at genome-wide significance (P = 2.7 x 10(-8) to P = 2.3 x 10(-13)) four new PP loci (at 4q12 near CHIC2, 7q22.3 near PIK3CG, 8q24.12 in NOV and 11q24.3 near ADAMTS8), two new MAP loci (3p21.31 in MAP4 and 10q25.3 near ADRB1) and one locus associated with both of these traits (2q24.3 near FIGN) that has also recently been associated with SBP in east Asians. For three of the new PP loci, the estimated effect for SBP was opposite of that for DBP, in contrast to the majority of common SBP- and DBP-associated variants, which show concordant effects on both traits. These findings suggest new genetic pathways underlying blood pressure variation, some of which may differentially influence SBP and DBP

Large-scale gene-centric analysis identifies novel variants for coronary artery disease

Coronary artery disease (CAD) has a significant genetic contribution that is incompletely characterized. To complement genome-wide association (GWA) studies, we conducted a large and systematic candidate gene study of CAD susceptibility, including analysis of many uncommon and functional variants. We examined 49,094 genetic variants in ~2,100 genes of cardiovascular relevance, using a customised gene array in 15,596 CAD cases and 34,992 controls (11,202 cases and 30,733 controls of European descent; 4,394 cases and 4,259 controls of South Asian origin). We attempted to replicate putative novel associations in an additional 17,121 CAD cases and 40,473 controls. Potential mechanisms through which the novel variants could affect CAD risk were explored through association tests with vascular risk factors and gene expression. We confirmed associations of several previously known CAD susceptibility loci (eg, 9p21.3:p<10; LPA:p<10; 1p13.3:p<10) as well as three recently discovered loci (COL4A1/COL4A2, ZC3HC1, CYP17A1:p<5×10). However, we found essentially null results for most previously suggested CAD candidate genes. In our replication study of 24 promising common variants, we identified novel associations of variants in or near LIPA, IL5, TRIB1, and ABCG5/ABCG8, with per-allele odds ratios for CAD risk with each of the novel variants ranging from 1.06-1.09. Associations with variants at LIPA, TRIB1, and ABCG5/ABCG8 were supported by gene expression data or effects on lipid levels. Apart from the previously reported variants in LPA, none of the other ~4,500 low frequency and functional variants showed a strong effect. Associations in South Asians did not differ appreciably from those in Europeans, except for 9p21.3 (per-allele odds ratio: 1.14 versus 1.27 respectively; P for heterogeneity = 0.003). This large-scale gene-centric analysis has identified several novel genes for CAD that relate to diverse biochemical and cellular functions and clarified the literature with regard to many previously suggested genes. © 2011 Butterworth et al

Empagliflozin in Patients with Chronic Kidney Disease

Background The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. Methods We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m(2) of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m(2) with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. Patients were randomly assigned to receive empagliflozin (10 mg once daily) or matching placebo. The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to &lt; 10 ml per minute per 1.73 m(2), a sustained decrease in eGFR of &amp; GE;40% from baseline, or death from renal causes) or death from cardiovascular causes. Results A total of 6609 patients underwent randomization. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P &lt; 0.001). Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.86; 95% CI, 0.78 to 0.95; P=0.003), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure or death from cardiovascular causes (which occurred in 4.0% in the empagliflozin group and 4.6% in the placebo group) or death from any cause (in 4.5% and 5.1%, respectively). The rates of serious adverse events were similar in the two groups. Conclusions Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo